Market Place
Sourcing Support
All News #Library
Biotech
Debiopharm To Present DDR Inhibition, Dual Payload ADCs, And AI
14 Apr 2026 //
PHARMIWEB
Debiopharm Deploys Genialis for AI-Based Biomarker Discovery
11 Jan 2026 //
PHARMIWEB
Debiopharm Initiates Phase III Trial For Acromegaly Treatment
04 Dec 2025 //
BUSINESSWIRE
Debiopharm Boosts Japanese Cancer Research With "Ideal Japan"
18 Nov 2025 //
BUSINESSWIRE
Debiopharm Completes Children`s CPP: Phase III Trial Enrollment
06 Nov 2025 //
BUSINESS WIRE
Debiopharm, NetTargets Partner to Advance Next-Gen ADCs
30 Oct 2025 //
BUSINESSWIRE
Debiopharm Licenses Sunrock`s Anti-Her3/her2 Antibody
30 Sep 2025 //
BUSINESSWIRE
ITM and Debiopharm Start Imaging Arm in Ph1/2 ccRCC Trial
23 Jun 2025 //
GLOBENEWSWIRE
Debiopharm Alkyon Join Forces on Radioligand Therapies
12 Jun 2025 //
BUSINESSWIRE
MEDSIR, Debiopharm Dose First Patient In WIN-B Breast Cancer Trial
25 Feb 2025 //
BUSINESSWIRE
Debiopharm & WhiteLab Partner For Oncology Drug Design
16 Sep 2024 //
BUSINESSWIRE
ITM Licenses CA IX-Targeted Radiopharmaceuticals From Debiopharm
12 Sep 2024 //
GLOBENEWSWIRE
Debiopharm, Genome Agree On First-In-Class Oncology ADC Family
03 Jun 2024 //
BUSINESSWIRE
MEDSIR, Debiopharm: Breast Cancer Combination Therapy Exploration
28 May 2024 //
BUSINESSWIRE
Debiopharm Extends SunRock Biopharma Partnership for ADC
08 Jan 2024 //
BUSINESSWIRE
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates
21 Sep 2023 //
BUSINESSWIRE
Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective Wee1 Inhibitor
17 May 2023 //
PR NEWSWIRE
Debiopharm Extends Dna Damage Repair Footprint With Oncology Pipeline Entry
02 Mar 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.